KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:PHI1 • NL0000009538

27.57 EUR
+2.91 (+11.8%)
Last: Feb 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

PHI1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. PHI1 may be in some trouble as it scores bad on both profitability and health. PHI1 has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • In the past year PHI1 had a positive cash flow from operations.
  • In multiple years PHI1 reported negative net income over the last 5 years.
  • PHI1 had a positive operating cash flow in 4 of the past 5 years.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

1.2 Ratios

  • With a Return On Assets value of 0.63%, PHI1 is not doing good in the industry: 63.49% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of 1.56%, PHI1 is doing worse than 63.49% of the companies in the same industry.
  • The Return On Invested Capital of PHI1 (3.95%) is worse than 61.90% of its industry peers.
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROIC 3.95%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.93%, PHI1 is doing worse than 63.49% of the companies in the same industry.
  • PHI1 has a Operating Margin of 6.10%. This is in the lower half of the industry: PHI1 underperforms 60.32% of its industry peers.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • PHI1's Gross Margin of 43.49% is on the low side compared to the rest of the industry. PHI1 is outperformed by 77.78% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PHI1 is higher compared to a year ago.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.09 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PHI1 has a Altman-Z score of 2.09. This is comparable to the rest of the industry: PHI1 outperforms 46.03% of its industry peers.
  • PHI1 has a debt to FCF ratio of 14.51. This is a negative value and a sign of low solvency as PHI1 would need 14.51 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 14.51, PHI1 is not doing good in the industry: 60.32% of the companies in the same industry are doing better.
  • PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1 has a worse Debt to Equity ratio (0.69) than 73.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Altman-Z 2.09
ROIC/WACC0.61
WACC6.49%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1 has a worse Current ratio (1.32) than 61.90% of its industry peers.
  • A Quick Ratio of 0.86 indicates that PHI1 may have some problems paying its short term obligations.
  • PHI1 has a Quick ratio of 0.86. This is in the lower half of the industry: PHI1 underperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.86
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
  • PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
  • PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -1.43%.
  • The Revenue has been growing slightly by 1.00% on average over the past years.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.28% on average over the next years. This is quite good.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.00% on average per year.
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 18.63, PHI1 is valued on the expensive side.
  • PHI1's Price/Earnings ratio is rather cheap when compared to the industry. PHI1 is cheaper than 84.13% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.03, PHI1 is valued a bit cheaper.
  • PHI1 is valuated rather expensively with a Price/Forward Earnings ratio of 18.12.
  • 65.08% of the companies in the same industry are more expensive than PHI1, based on the Price/Forward Earnings ratio.
  • PHI1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.97, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.63
Fwd PE 18.12
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • PHI1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 65.08% of the companies in the same industry.
  • PHI1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 45.93
EV/EBITDA 14.12
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)3.77
PEG (5Y)N/A
EPS Next 2Y4.81%
EPS Next 3Y7.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/10/2026, 7:00:00 PM)

27.57

+2.91 (+11.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)02-10
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap26.55B
Revenue(TTM)17.78B
Net Income(TTM)165.00M
Analysts72.14
Price Target27.26 (-1.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP199.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.57%
Min EPS beat(2)14.1%
Max EPS beat(2)31.04%
EPS beat(4)3
Avg EPS beat(4)13.85%
Min EPS beat(4)-11.97%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-0.89%
EPS beat(12)6
Avg EPS beat(12)18.79%
EPS beat(16)6
Avg EPS beat(16)4.51%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-1.97%
Revenue beat(4)0
Avg Revenue beat(4)-2.34%
Min Revenue beat(4)-3.04%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-1.64%
Revenue beat(16)2
Avg Revenue beat(16)-1.76%
PT rev (1m)-1.52%
PT rev (3m)-1.03%
EPS NQ rev (1m)1.37%
EPS NQ rev (3m)5.07%
EPS NY rev (1m)0.57%
EPS NY rev (3m)4.69%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.35%
Valuation
Industry RankSector Rank
PE 18.63
Fwd PE 18.12
P/S 1.49
P/FCF 45.93
P/OCF 21.64
P/B 2.52
P/tB N/A
EV/EBITDA 14.12
EPS(TTM)1.48
EY5.37%
EPS(NY)1.52
Fwd EY5.52%
FCF(TTM)0.6
FCFY2.18%
OCF(TTM)1.27
OCFY4.62%
SpS18.47
BVpS10.96
TBVpS-1.42
PEG (NY)3.77
PEG (5Y)N/A
Graham Number19.1
Profitability
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROCE 5.61%
ROIC 3.95%
ROICexc 3.95%
ROICexgc 10.33%
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
FCFM 3.25%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Debt/EBITDA 2.93
Cap/Depr 46.69%
Cap/Sales 3.65%
Interest Coverage 250
Cash Conversion 49.6%
Profit Quality 350.3%
Current Ratio 1.32
Quick Ratio 0.86
Altman-Z 2.09
F-ScoreN/A
WACC6.49%
ROIC/WACC0.61
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%
EBIT growth 1Y712.43%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.95%
EBIT Next 3Y19.49%
EBIT Next 5Y15.13%
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 199.39%.